A 336-amino-acid segment of the GB virus C second envelope protein (E2) has been produced in BHK-21 cells using the Semliki Forest virus vector system. Secretion of this protein was facilitated by deletion of a hydrophobic region at the Cterminus that may represent the membrane anchoring domain. The E2 protein recovered from the culture supernatant exhibited a molecular mass of approximately 52 kDa, with the increase in size relative to the polyprotein backbone being contributed by N-linked glycosylation. A radioimmunoprecipitation assay using GBV-C E2 was developed to test for the presence of antibodies against this protein in human sera. The prevalence of antibodies to E2 was high among injection drug users and other individuals at risk for acquiring parenterally transmitted agents. There was a much higher percentage of anti-E2 seropositivity in GBV-C RT-PCR negative compared to GBV-C RT-PCR positive samples from these populations. In addition, serial samples from patients transfused with blood containing GBV-C showed seroconversion to anti-E2 positivity and loss of GBV-C viremia as measured by RT-PCR within 11 months of transfusion in five of seven individuals. Thus, this system provided a rapid means to identify GBV-C E2 as a useful antigen for the study of GBV-C exposure. ᭧ 1996 Academic Press, Inc.
INTRODUCTION
been hampered since only about 25% of GBV-C infected individuals develop antibodies to Escherichia coli-ex-GB virus C (GBV-C) is a newly described human virus pressed GBV-C proteins in their sera as detected by which possesses a single-stranded RNA genome apWestern blot or solid-phase enzyme-linked immunosorproximately 10 kb in size. GBV-C has been tentatively bent assay (ELISA) ; Pilot-Matias et classified as belonging to a virus group within the Flavial., 1996) . Most of the seropositive individuals produce viridae containing hepatitis C virus (HCV) and two other antibodies against only a single antigen. In addition, no viruses isolated recently, designated GB virus A (GBV-A) single GBV-C antigen has been identified thus far that is and GB virus B (GBV-B) consistently recognized by individuals who have been al., 1995; Simons et al., 1995a,b) . The newly described exposed to GBV-C. However, the current immunoassays hepatitis G virus (Linnen et al., 1996) appears to be an are limited by the use of GBV-C proteins that have been isolate of GBV-C (Zuckerman, 1996) . Studies indicate that denatured during purification. In addition, the structural GBV-C is found in the sera of commercial plasma donors, proteins currently in use are not glycosylated. people at risk for parenterally transmitted infectious
The phylogenetic relatedness of GBV-C and HCV sugagents such as injection drug users, and some individugested that useful serologic markers for GBV-C infection als with hepatitis of unknown origin  may be identified in regions homologous to those identi- Simons et al., 1995a; Yoshiba, Oka- fied as useful for HCV. One of the most important markers moto, and Mishiro, 1995) .
for HCV is the nucleocapsid or core protein (Chiba et al., Although some regions of GBV-C have been identified 1991; Nasoff et al., 1991; and others) . However, GBV-C as immunogenic (Pilot-Matias et al., 1996) , efforts to dedoes not appear to encode a core-like protein (Erker et velop an immunoassay for the detection of GBV-C have al., 1996; Simons et al., 1996) . Glycosylated E2 protein is another useful marker in HCV infection (Lesniewski et al., 1995; Lok et hamster kidney (BHK-21) cells using the Semliki Forest virus (SFV) vector system (Liljestrom and Garoff, 1991) . The protein was secreted and glycosylated. A sensitive and specific radioimmunoprecipitation assay (RIPA) was developed and shown to be useful in identifying individuals who have been exposed to GBV-C.
MATERIALS AND METHODS

Rabbit and human antisera
Rabbit antisera were generated as follows: 15-weekold female New Zealand white rabbits weighing 2-3 kg were inoculated both intramuscularly and subcutaneously for all injections, with 1 mg primary inocula followed by 0.2-to 0.5-mg boosts at 1, 2, and 4 months. Three different hyperimmune rabbit sera reactive with GBV-C E2 were used. The first rabbit (10363) was immu- as shown. The upstream overhang was compatible with a BamHI site, but after ligation the regenerated sequence was GGATCA. This allowed 1572850) expressed in E. coli as a CKS fusion protein as insertion of a fragment encoding GBV-C E2 into the unique BamHI previously described . The second site downstream of the lysozyme signal sequence. The plasmid was rabbit (10365) was immunized with a 30-mer synthetic linearized at the unique SpeI restriction site prior to RNA transcription peptide derived from the E2 region of GBV-C, encomusing the SP6 promoter.
passing amino acids 335-364. The third rabbit (10692) was immunized with a purified 315-amino-acid portion performed with the Ausria II assay and the antibodies of GBV-C E2 (amino acids 204-518; E2-315) expressed against HBV core antigen were determined with the Corin and secreted from Chinese hamster ovary (CHO) cells. zyme test. All tests are commercially available from AbTwo hyperimmune rabbit sera reactive with HCV E2 were bott Laboratories, North Chicago, Illinois. The details of used. The first (6512) was generated by immunization the GBV-C E2 and HCV E2 ELISAs have been presented with a 43-mer synthetic peptide encompassing amino elsewhere (Dille et al., 1996; Lesniewski et al., 1995) . acids 509-551 of HCV-1 and the second (9482) was genConditions for reverse-transcription-polymerase chain erated by immunization with purified HCV E2 protein exreaction (RT-PCR) on human serum samples were prepressed in and secreted from CHO cells (Lesniewski et viously described (Dawson et al., ). al., 1995 . The endpoint titer for each rabbit serum ranged from 1 1 10 7 /ml to 5 1 10 7 /ml against the homologous SFV expression plasmid construction immunogen.
Human sera from individuals considered at low risk for The human lysozyme secretion signal was inserted exposure to GBV-C were obtained from volunteer blood into the pSFV1 expression plasmid (Gibco-BRL; Grand donors residing in the United States. These specimens Island, NY) by cloning of an oligonucleotide duplex into had normal serum alanine aminotransferase (ALT) levels BamHI-digested pSFV1 as shown in Fig. 1 . When the (£50 IU/ml) and were unreactive for hepatitis B (HBV) resulting plasmid, pSFV-ss, was digested with BamHI, surface antigen, antibodies to HBV core, and antibodies the upstream site was not cut due to a mutation in the to HCV. Human sera from several populations considBamHI recognition site. This allowed cloning of the GBVered at risk of acquiring parenterally transmitted viruses C E2 gene at the downstream BamHI site such that the were previously described . These first amino acid encoded by the E2 gene followed the included specimens from injection drug users, commersignal peptidase cleavage site encoded by the lysozyme cial plasma donors, individuals who had received multisignal sequence-plus 2 linker amino acids encoded by ple transfusions, and individuals with cryptogenic nonthe restriction site. A-E hepatitis. Sera from individuals transfused with GBV-A fragment encoding amino acid residues 204-539 of C were from the Transfusion-Transmitted Viruses Study the GBV-C polyprotein (GBV-C E2-336) was generated by (Aach et al., 1991) .
PCR from a plasmid template using primers 5-AAA-ATTGGATCCAGGCGCGCCCGCCTCAGTGTTG and 5-Enzyme immunoassays and RT-PCR AAAACCGGATCCTTACGGAATGAAGTTGCCCGCATCC at 1 mM for 25 cycles (94Њ for 20 sec; 55Њ for 30 sec; 72Њ Testing for HCV was performed with an HCV EIA second generation assay. HBV surface antigen testing was for 60 sec). The resulting PCR fragment was digested with BamHI (sites are underlined in primer sequences) flask, and incubated at 37Њ and 5% CO 2 . Transfection efficiencies were routinely observed to be 95-100% usand ligated into BamHI-digested pSFV-ss, resulting in plasmid pSFV-ss/E2-336. The sequence was confirmed ing RNA derived from the Lac-Z positive control plasmid pSFV3-lacZ and b-galactosidase assay reagents as supusing an ABI Prism Dye Terminator Cycle Sequencing Ready Reaction Kit and an ABI 373 automated sequencer plied and described by Gibco-BRL. (Perkin-Elmer, Corp.; Foster City, CA).
Metabolic labeling of transfected BHK-21 cells A fragment encoding amino acid residues 388-664 of the HCV-1 polyprotein (HCV E2-277) was generated by After incubation at 37Њ and 5% CO 2 for 5 hr, the growth PCR from a plasmid template using primers 5-AAAmedium was removed and the cells were washed three ATTGGATCCCACCGGGGGAAGTGCCGGCCAC and 5-times with D-PBS with calcium and magnesium (Gibco-AAAACCGGATCCTTACGGGCTGAGCTCGGACCTGTC BRL). Cells were overlaid with minimum essential meusing the same conditions as above. The PCR fragment dium (MEM) without cysteine (MEM Select-Amine kit, was cloned (resulting in plasmid pSFV-ss/HCV-E2-277) Gibco-BRL analyzed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) under reducing conditions using standard Maryland. Cells were cultured in growth medium (Glasgow minimum essential medium with 2 mM glutamine, methods and reagents. After electrophoresis, gels were fixed in 10% acetic acid/40% methanol, dried, and ana-10% tryptose phosphate broth, 5% fetal calf serum, 30 mM HEPES, 100 U/ml penicillin/streptomycin) (Gibco-BRL) at lyzed using a Molecular Dynamics PhosphorImager (Sunnyvale, CA). Quantitation of individual bands was 37Њ and 5% CO 2 . Cells were harvested by removing the growth medium and rinsing three times with Dulbecco's done using ImageQuaNT, Version 4.2 software (Molecular Dynamics). RIPAs were performed on labeled cell phosphate-buffered saline without calcium and magnesium (D-PBS) (Gibco-BRL). Cells were then treated with supernatants as follows: Supernatants were preincubated for 1 hr at 4Њ with Pansorbin cells (Calbiochem trypsin EDTA (Gibco-BRL) for 5 min and the trypsin and cell suspension were decanted. The cell suspension was Corp.; La Jolla, CA). After centrifuging for 10 min at 10,000 g, an aliquot of the preadsorbed supernatant was mixed neutralized with growth medium and centrifuged at 1000 g to pellet the cells.
with 2-8 ml of rabbit or human serum and incubated at 4Њ for 2-4 hr. Protein A-agarose beads (Boehringer For transfection, cells were grown to mid-log phase in 860-cm 2 roller bottles and harvested from the culture Mannheim; Indianapolis, IN) were added and tubes were incubated at 4Њ for 1 hr with rocking. The protein Avessel as described above. After three D-PBS washes, cell density was adjusted to 1 1 10 7 cells in 0.8 ml of Dagarose beads were pelleted and washed twice with lysis buffer (0.2% NP-40, 50 mM Tris, pH 8.0, 150 mM PBS. Cells were kept at room temperature for not more than 30 min before electroporation. Approximately 5-10 NaCl), once with lysis buffer containing 0.2% SDS, once with lysis buffer containing 500 mM NaCl and finally once mg of RNA was mixed with the 0.8 ml of cell suspension and immediately electroporated at 1250 V, 25 mF with with H 2 O. The beads were resuspended in sample buffer (62.5 mM Tris, pH 6.8, 2% SDS, 10% glycerol, 5% b-merthree manual pulses using a Gene Pulser (Bio-Rad; Hercules, CA) and a 4-cm Gene Pulser cuvette. After 5 min captoethanol, and 0.1 mg/ml bromophenol blue) and heated at 95Њ for 5 min. Supernatants were run on SDSat room temperature in the electroporation cuvette, cells were transferred to growth medium, planted in a T-75 PAGE, fixed, dried, and analyzed as described above.
For the deglycosylation experiment, the antibody-GBV-C E2-336 protein complex was removed from the protein A-agarose beads by heating at 95Њ for 5 min in 0.5% SDS, 50 mM b-mercaptoethanol, 50 mM Tris, pH 8.0. Two volumes of 2% NP-40 in 50 mM Tris, pH 8.0, was added, followed by the addition of 0.5 units of recombinant N-glycanase (Genzyme; Cambridge, MA) and incubation at 37Њ for 18 hr. Sample buffer was added, followed by SDS-PAGE and PhosphorImaging as above. A control reaction without the enzyme was performed under the same conditions.
Purification of proteins expressed in CHO cells
Expression of a C-terminally truncated HCV E2 protein (HCV E2-277) in CHO cells using the SV-HCL vector and purification using successive cation, anion, and lectin affinity chromatographies was previously described (Lesniewski et al., 1995) . Expression of GBV-C E2-315 in CHO cells using the SV-HCL vector and purification by immunoaffinity chromatography using a monoclonal antibody directed against a FLAG peptide encoded at the C-terminus of the protein is described in detail elsewhere (Surowy et al., manuscript in preparation) . The N-terminus of the purified CHO cell-derived GBV-C E2-315 has been sequenced and found to be correct (Surowy et al., manuscript in preparation).
RESULTS
Expression of GBV-C E2 protein and analysis of Nlinked glycosylation
A 336-amino-acid segment of the GBV-C E2 antigen was expressed in BHK-21 cells using the Semliki Forest virus expression system and the human lysozyme secretion signal sequence. The E2 protein was truncated just Fig. 2A, lanes 1 and 2) . The 35-to 46-and 48-to 56-were used to immunoprecipitate pSFV-ss/E2-336 supernatant (B) or kDa proteins were specifically precipitated from the lypSFV-ss/HCV-E2-277 supernatant (C) and analyzed by 10% SDS-PAGE. sate and supernatant, respectively, with hyperimmune Lanes 1, 3, 5, 7, and 9 are RIPAs with preimmune rabbit sera and lanes anti-GBV-C E2 rabbit serum 10363, but not with the pre-2, 4, 6, 8, and 10 are RIPAs with hyperimmune rabbit sera as indicated.
immune serum from the same rabbit ( 35-to 46-and 48-to 56-kDa bands in the lysate and supernatant, respectively, approximately 30-35% of the E2 made during the 48-hr labeling period was secreted lysate and supernatant were glycosylated. However, the protein remaining inside the cell (lysate) exhibited a from the cells into the medium.
The diffuse nature of the bands and the increased size lower molecular mass than the secreted form, indicating that further processing had occurred during secretion. relative to that predicted for unmodified protein (36 kDa) suggested that the GBV-C E2-336 proteins seen in the To confirm that the SFV-expressed GBV-C E2-336 was glycosylated, the protein found in the supernatant was immunoprecipitated using anti-GBV-C E2 rabbit serum 10363 and then treated with N-glycanase ( Fig. 2A, lane  8) . A molecular mass shift from approximately 52 kDa to approximately 35 kDa was noted after the treatment, suggesting that the increase in size of the E2 protein found in the supernatant was due to the presence of Nlinked oligosaccharides.
Specificity of GBV-C and HCV E2 RIPAs
In order to demonstrate the specificity of our assays, RIPAs were performed with several additional sera. The 48-to 56-kDa protein in the supernatant was precipitated with GBV-C E2 reactive sera from two other hyperimmune rabbits (10365 and 10692) in addition to rabbit 10363 serum (Fig. 2B, lanes 8 and 10) . Hyperimmune sera from all three of these rabbits react with purified GBV-C E2- (Fig. 2B, lanes 2 and 4) . In ( Fig. 2C, lanes 2 and 4) .
Specificity was demonstrated by RIPAs with four human sera as well. The first of these was from an injection mg) of purified, unlabeled CHO cell-derived GBV-C E2-drug user whose serum was immunoreactive with both 315 protein but not by an equivalent amount of purified, CHO cell-derived GBV-C E2-315 by ELISA (Dille et al., unlabeled CHO cell-derived HCV E2-277 protein. Based 1996) and CHO cell-derived HCV E2-277 by ELISA (unon quantitation of the individual bands using Impublished data), while the second was from an injection ageQuaNT software, greater than 95% of the reactivity drug user whose serum was immunoreactive with HCV with the GBV-C E2 protein was blocked in all four sam-E2-277 (unpublished data) but not with GBV-C E2-315 by ples, again demonstrating the specificity of the anti-GBV-ELISA (Dille et al., 1996) . The third and fourth human C E2 reactivity in these samples. serum specimens were from volunteer blood donors, one of whom was shown to be anti-HCV E2-277 negative Anti-GBV-C E2 seroprevalence in injection drug users (unpublished data) and anti-GBV-C E2-315 positive by ELISA (Dille et al., 1996) , while the other was negative Sera from 40 injection drug users were tested by RIPA using the pSFV-ss/E2-336 supernatant. The seroprevafor both proteins by ELISA. RIPA results with these four sera (Figs. 2B and 2C, lanes 11-14) in each case conlence of antibodies to HCV (99%) and HBV (75%) indicated that this population is at very high firmed the results previously determined by ELISA, thus verifying the specificity of the RIPA assays.
risk of exposure to parenterally transmitted agents. Twenty-nine of the 40 specimens (72.5%) were anti-GBVIn order to rule out the possibility that the GBV-C E2-336 RIPA was detecting crossreactive HCV E2 antibod-C E2 positive (Table 1) . Of these 29 immunoreactive samples, 27 were GBV-C RT-PCR negative. RIPA results from ies, a blocking experiment was performed on four serum samples (three anti-HCV E2 positive injection drug users six of the 27 GBV-C RT-PCR negative specimens are shown in Fig. 3A (lanes 1-6) . The results from 6 of the and one anti-HCV E2 negative volunteer blood donor) using purified, CHO cell-derived GBV-C or HCV E2 pro-13 GBV-C RT-PCR positive specimens are also shown in Fig. 3A (lanes 7-12) , including 1 of the 2 individuals tein (Fig. 3B) . Immunoprecipitation of radiolabeled GBV-C E2-336 protein was inhibited by an excess (0.4-4.0 who were both GBV-C RT-PCR positive and anti-E2-336 addition, a sample from G.B. taken more than 30 years later was still weakly positive in the GBV-C E2-336 RIPA (data not shown).
Number of Number (%) E2 Category samples RIPA Positive A total of 60 specimens from the commercial plasma donor population were tested for antibodies to GBV-C Injection drug users E2. Twenty-one of these samples were not included in GBV-C PCR positive 13 2 (15.4%) determined. In the E2 testing, the RIPA using the GBV-C Non-A-E hepatitis GBV-C PCR positive 9 2 (22.2%) E2-336 protein expressed in BHK-21 cells and the ELISA GBV-C PCR negative 5 2 (40%) using the GBV-C E2-315 protein expressed in CHO cells
Commercial plasma donors/multiply (Dille et al., 1996) were directly compared. Of the 60 transfused individuals samples, 33 were positive in both assays while 27 were GBV-C PCR positive 18 2 (11.1%) negative in both assays. Thus, a 100% correlation in reac-GBV-C PCR negative 24 12 (50%) Volunteer blood donors tivity was observed on this set of samples between the GBV-C PCR positive 1 0 (0%) two systems, supporting the GBV-C E2 specificity of the GBV-C PCR negative 59 2 (3.4%) assays.
Note. All volunteer blood donors were screened negative for HBsAg
Anti-GBV-C E2 seroprevalence in low risk patients and for antibodies to HCV, HIV, and HBc.
Sera from 60 volunteer blood donors who were considered at low risk for parenterally transmitted agents and positive (lane 8). In this specimen, the anti-E2-336 reactivwho tested negative for HBV, HCV, and HIV were also ity was weak. An additional sample taken approximately tested by the GBV-C E2-336 RIPA (Table 1 ). There was 3 years later was available from each of the 2 individuals one GBV-C RT-PCR positive sample in this population, who were both RT-PCR and RIPA positive. These new and this specimen was found to be GBV-C E2-336 RIPA samples were tested for both presence of viral RNA and negative. In contrast, two GBV-C RT-PCR negative samfor anti-E2 antibodies. The new sample from each individples from this population were immunoreactive with GBVual remained GBV-C RT-PCR positive and weakly anti-C E2-336, one strongly reactive and one very weakly E2-336 positive (data not shown). Nonetheless, a majority reactive. The RIPA of the strongly reactive specimen is (11 of 13) of the GBV-C RT-PCR positive (i.e., viremic) shown in Fig. 2B , lane 13 and in Fig. 3A , lane 13. A RIPA samples from the injection drug users were GBV-C E2-was also performed with this sample using the SFV-336 RIPA negative and all of the GBV-C RT-PCR negative expressed HCV E2-277 protein. As shown in Fig. 2C , lane samples from the injection drug users were GBV-C E2-13, this sample was not reactive with HCV E2-277. Thus, 336 RIPA positive.
the prevalence of exposure to GBV-C in this volunteer donor population as detected by RT-PCR plus E2-336 Anti-GBV-C E2 seroprevalence in additional high risk RIPA was 5%. patients
RIPAs with the GBV-C E2-336 protein were performed
Anti-GBV-C E2 seroprevalence in patients transfused on sera from an additional 56 patients including commerwith GBV-C cial plasma donors and individuals who had received multiple blood transfusions, as well as on some individuRIPAs were performed with the pSFV-ss/E2-336 supernatant using serial blood samples from seven patients als with cryptogenic non-A-E hepatitis (Table 1) . Of the 27 GBV-C PCR positive samples who were all RT-PCR negative for GBV-C prior to transfusion. Subsequent to transfusion with blood containing in this group, 4 (14.8%) were anti-GBV-C E2-336 positive by RIPA. Nine of the 27 PCR positive samples were from GBV-C, each of these seven individuals became GBV-C RT-PCR positive within 3 months; four of the seven were individuals with non-A-E hepatitis and 2 of these 9 (22.2%) were GBV-C E2-336 RIPA positive. The remaining 29 PCR positive within 3 weeks. Several of these individuals developed elevated liver enzymes during the time when samples in this group were GBV-C PCR negative, and of these 14 (48.3%) were GBV-C E2-336 RIPA positive. Five they were GBV-C RT-PCR positive (Mosley et al., manuscript in preparation) . GBV-C E2-336 RIPA data on the of the 29 PCR negative samples were from individuals with non-A-E hepatitis and 2 of these 5 (40%) were GBVpatients are shown in Table 2 and Fig. 4 . Six of the seven patients (patients 1-6) developed immunoreactivity C E2-336 RIPA positive. One interesting finding was that an 8-week postpresentation sample from G.B., the suragainst the GBV-C E2-336 protein during the study period, and five of these six individuals (patients 1-5) begeon whose serum originally induced hepatitis in tamarins, leading to the isolation of GBV-A and GBV-B came GBV-C RT-PCR negative by their last available sample. The time range within which these five individu- (Schlauder et al., 1995; Simons et al., 1995b) , was strongly positive by RIPA for GBV-C E2-336 protein.
In als became GBV-C RT-PCR negative was from 6 to 11 
months after transfusion. Patient 5 was found to be patients 6 and 7 eventually became GBV-C RT-PCR negative or whether they remained positive for GBV-C RNA. weakly anti-E2-336 positive prior to transfusion, perhaps indicating a past exposure to GBV-C. Patients 6 and 7
Patient 6 showed a weak, transient reactivity to E2-336 early after infection. One of this patient's donors was were still GBV-C RT-PCR positive on the last date of sample availability. Patient 7 exhibited no immunoreacstrongly immunoreactive with E2-336, so the observed reactivity may have resulted from carry-over of anti-E2 tivity to the GBV-C E2-336 protein.
No further specimens were available from these paantibodies from this donor. In addition, due to lack of sample availability, it was not possible to determine the tients. Therefore, it was not possible to ascertain whether lieved to closely resemble its native conformation and to develop a sensitive RIPA to detect the presence in human sera of antibodies directed at this protein. A soluble, glycosylated form of the GBV-C E2 protein was secreted into the cell culture medium. Secretion was facilitated by truncating the protein just upstream of the putative hydrophobic membrane anchoring domain at the C-terminus. This strategy is analogous to that used to successfully secrete HCV E2 protein (Lesniewski et al., 1995; Spaete et al., 1992) .
We have expressed in the SFV system the same 277-amino-acid region of the HCV E2 protein previously produced in CHO cells (Lesniewski et al., 1995) and used it to demonstrate the specificity of our RIPA assay using hyperimmune rabbit sera as well as human sera. Additionally, a blocking experiment in which an excess of unlabeled GBV-C or HCV E2 protein was added to the GBV-C E2-336 RIPA demonstrated that the immunoprecipitation of GBV-C E2 protein by antibodies in the four samples examined was not due to cross-reactivity with data were available for each . Larger the two assays were weakly positive in the RIPA assay and fell just below the cutoff set for the ELISA, indicating that the sensitivity of the RIPA is very similar to that overlap between PCR positivity and anti-E2-336 reactivity obtained in the ELISA (unpublished data). in patients 2, 3, and 4 in the time period between the Results from our RIPA indicate that mammalian celllast two bleeds, which were several months apart. expressed E2 protein is much more effective than E. coliexpressed E2 protein at detecting individuals exposed DISCUSSION to GBV-C and in fact is the only seroconversion marker thus far identified. Several of the The SFV expression system has advantages over samples identified by the GBV-C E2-336 RIPA were also many other mammalian cell expression systems in examined by Western blot analysis with CHO cell-exallowing rapid generation of constructs and in preferenpressed GBV-C E2-315 (Surowy et al., manuscript in tially producing the protein of interest due to attenuation preparation). Although concordance was seen on 7 samof host cell protein synthesis. This is at least partially ples of the 20 GBV-C E2-336 RIPA positive samples exdue to the fact that the SFV subgenomic RNA containing amined, there were 13 E2 RIPA positive and ELISA posithe cloned gene becomes the most abundant mRNA in tive samples which were negative by Western blot, indithe cell, recruiting a large portion of the cell's translacating the importance of conformational epitopes on the tional machinery. Additional mechanisms may also play E2 protein for the detection of antibodies to E2. Similar a role in the selective shut-down of host-specific protein observations have been made for HCV and various flavisynthesis (Sjoberg and Garoff, 1996) . This analytical sysviruses, where at least some of the epitopes on the envetem has allowed us to rapidly express a 336-amino-acid C-terminally truncated GBV-C E2 antigen in a form belope proteins are conformational in nature (Chien et al., 1993; Guirakhoo, Heinz, and Kunz, 1989; Hall et al., 1990;  true causal link between the appearance of antibodies to E2 and the loss of detectable GBV-C RNA in the serum, Lesniewski et al., 1995; Nowak and Wengler, 1987) .
One hundred percent of the specimens examined from nor if individuals who become infected with GBV-C and then mount an immune response to E2 and subsequently the injection drug user population were either GBV-C RT-PCR positive or anti-GBV-C E2 antibody positive, indicatclear the virus will have long-lasting protection from reinfection. ing a very high level of exposure to GBV-C, similar to the high level of exposure to other parenterally transmitted There is a striking difference in the amount of sequence variation found among GBV-C E2 proteins relahepatitis agents seen in individuals from this population . Relatively high levels of exposure tive to that observed for HCV. E2 proteins from various HCV isolates may have sequence identities as low as to GBV-C were also indicated by the seroprevalence of antibodies to GBV-C E2 in commercial plasma donors 70%. In addition, a hypervariable region has been identifed near the N-terminus of HCV E2 which is believed (33.3%) and non-A-E hepatitis patients (28.6%). The majority of E2 seropositive samples from these three populato allow the virus to ''escape'' neutralizing antibodies (Farci et al., 1992; Weiner et al., 1992) . No such hypervaritions (41 of 47) were GBV-C RT-PCR negative. The observation that most of the individuals who possess antibodable region has been found in the GBV-C E2 protein.
When the E2 proteins from four geographically diverse ies to GBV-C E2 are GBV-C RT-PCR negative is in contrast to the results for HCV, in which most of the isolates of GBV-C were aligned, sequence identities were ú90% . The level of sequence individuals identified as seropositive for antibodies to HCV E2 are HCV RT-PCR positive (Lesniewski et al., variation observed between the E2 proteins from GBV-C isolates more closely resembles that observed with the 1995; Zaaijer et al., 1994) .
The development of antibodies to E2 and subsequent envelope proteins of flaviviruses such as Dengue 2 virus or pestiviruses such as bovine viral diarrhea virus loss of detectable viral RNA in five of the seven individuals transfused with GBV-C (Table 2) suggest that antibod- (Becher et al., 1994; Lewis et al., 1993) . This lack of sequence variation in GBV-C E2 implies that this virus does ies to the GBV-C E2 protein may be involved in or at least predictive of viral clearance. The PCR and RIPA not possess the ability to escape neutralizing antibodies in the same manner as HCV and thus may explain the data presented in Fig. 3 and Tables 1 and 2 are consistent with the hypothesis that most individuals who elicit apparent clearance of GBV-C in most individuals following detection of antibodies to the E2 protein. anti-E2 antibodies do not have virus present in the serum. However, we cannot rule out the possibility that the virus Individuals who have been exposed to GBV-C seem to segregate into two distinct populations. A majority of is still replicating, but that the titer in the serum has dropped below the limits of detection in our RT-PCR those exposed appear to resolve the viral infection. Most of these individuals mount an antibody response to the assay. In addition, the observation that one of the transfused patients (patient 5) was weakly immunoreactive E2 protein. Clearance of the virus may be due in part to the immune response to the E2 protein as well as to with GBV-C E2 prior to transfusion suggests that in this individual, the antibodies directed against E2 were not other mechanisms, such as T-cell mediated immunity. A smaller but nonetheless significant percentage of individprotective. This may have been due to the low antibody titer or to prior infection with a different serotype of GBVuals who contract GBV-C remain chronically infected and most of these individuals do not appear to mount a hu-C, or it may indicate that other immune responses in addition to antibodies directed at E2 are involved in the moral immune response to E2. However, 2 of the 40 injection drug users did not fit this profile. These individuresolution of GBV-C infection.
It is tempting to speculate that GBV-C may be similar to als were both GBV-C RT-PCR positive and E2 seropositive on two separate dates 3 years apart. Whether this flaviviruses such as dengue virus, Japanese encephalitis virus, or yellow fever virus in which the envelope protein was due to reinfection with GBV-C during the study period or whether these individuals were immunosupplays a dominant role in the generation of neutralizing antibodies and the induction of a protective immune repressed is not known. Although the number of samples examined in this sponse (reviewed in Monath and Heinz, 1996) . Similarly, the E2 protein of pestiviruses has been shown to be study was limited, a high prevalence rate for GBV-C was noted in the various high-and low-risk groups examined. the major target of neutralizing antibodies and induces protective immunity (Donis et al., 1988; Rumenapf et al., The combined PCR plus E2 antibody prevalence rate of 5% in the volunteer blood donor group is particularly 1991; Weiland et al., 1990) . This is in contrast to what has been observed for HCV where it was found that most noteworthy. The fact that GBV-C sometimes establishes a chronic infection coupled with the apparent efficiency individuals chronically infected with HCV have antibodies to E2 (Chien et al., 1993; Lesniewski et al., 1995) but that with which it is transmitted both parenterally Linnen et al., 1996; Schmidt et al., 1996) and HCV does not elicit neutralizing antibodies in at least 60% of cases (Choo et al., 1994; Farci et al., 1992 Farci et al., , 1994  vertically (Feucht et al., 1996) may explain this high prevalence of GBV-C exposure. Further studies will be neces- Rosa et al., 1996) . It is not yet known whether there is a
